Diagnostics inform nearly 70% of medical decisions — yet lab testing remains one of the most under-managed cost drivers in self-insured health plans.

According to Avalon’s 2025 Lab Trend Report, routine testing accounts for 90% of test volume, genetic testing drives up to 30% of spend, and site-of-service pricing can vary more than 5x for the exact same test.

At the same time, up to 30% of routine lab testing is unnecessary — contributing to downstream cost escalation, employee out-of-pocket burden, and employer dissatisfaction.

In this thought leadership session, Dr. Kristie Ressler, DO, Chief Medical Officer at Avalon, and Kerri Costa, MS, RN, SVP of Business Development, will explore:

• What diagnostic waste is, why it persists, and how overutilization and site-of-service variation drive unnecessary cost
• The financial and employee impact for self-insured employers and why lab benefits often go unmanaged
• How evidence-based diagnostic oversight can drive 8–10% savings across ASO lines of business while strengthening renewal conversations